Evosep and Agilent Technologies will collaborate to further improve their robust, high-throughput workflows for proteomics

Today, at the ASMS 2020 Reboot, Evosep and Agilent Technologies announce their joint efforts to improve robust, high-throughput workflows for clinical research proteomics. The initial data from the collaboration will be presented at the conference in poster ThP 489 as well as in an online webinar today (Register here)

Evosep and Agilent Technologies will collaborate to further improve their robust, high-throughput workflows for proteomics
Figure 1. Evosep One is a chromatography system that delivers fast, sensitive and robust proteomic analysis of clinical samples, while supporting connections to a wide range of mass spectrometers.

Mass spectrometry (MS)-based proteomics has become a central technology in biological research and it is now promising to become equally powerful for future clinical research, for instance through characterization of the plasma proteome and tissue proteomes in adequate depth. Proteomics as a technology may have lacked the speed and robustness necessary, but with recent advances in sample preparation and chromatography, accurate proteome quantitation in high throughput mode for thousands of samples is now possible.

The Evosep One separation solution fits perfectly with the routine focused applications developed by Agilent Technologies by enabling really high throughput sample separation for MS analyses while still being extremely easy to use for the customer. The combination of an Evosep One and an Agilent Technologies Mass Spectrometer, e.g. a triple Quadrupole, will enable ultra-robust, sensitive and fully automated workflows. What every lab would want and an important step forward for clinical research.”

Dr Nicolai Bache, Head of Application, Evosep elaborates

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Agilent Technologies. (2020, June 10). Evosep and Agilent Technologies will collaborate to further improve their robust, high-throughput workflows for proteomics. News-Medical. Retrieved on November 23, 2024 from https://www.news-medical.net/news/20200610/Evosep-and-Agilent-Technologies-will-collaborate-to-further-improve-their-robust-high-throughput-workflows-for-proteomics.aspx.

  • MLA

    Agilent Technologies. "Evosep and Agilent Technologies will collaborate to further improve their robust, high-throughput workflows for proteomics". News-Medical. 23 November 2024. <https://www.news-medical.net/news/20200610/Evosep-and-Agilent-Technologies-will-collaborate-to-further-improve-their-robust-high-throughput-workflows-for-proteomics.aspx>.

  • Chicago

    Agilent Technologies. "Evosep and Agilent Technologies will collaborate to further improve their robust, high-throughput workflows for proteomics". News-Medical. https://www.news-medical.net/news/20200610/Evosep-and-Agilent-Technologies-will-collaborate-to-further-improve-their-robust-high-throughput-workflows-for-proteomics.aspx. (accessed November 23, 2024).

  • Harvard

    Agilent Technologies. 2020. Evosep and Agilent Technologies will collaborate to further improve their robust, high-throughput workflows for proteomics. News-Medical, viewed 23 November 2024, https://www.news-medical.net/news/20200610/Evosep-and-Agilent-Technologies-will-collaborate-to-further-improve-their-robust-high-throughput-workflows-for-proteomics.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.